Lv3
350 积分 2023-08-04 加入
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
8小时前
待确认
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
8小时前
已完结
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
8小时前
已完结
Development of a highly potent and selective degrader of LRRK2
12天前
已完结
Development of a highly potent and selective degrader of LRRK2
1个月前
已完结
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers
1个月前
已完结
Characterization of a Protein Interactome by Co-Immunoprecipitation and Shotgun Mass Spectrometry
3个月前
已完结
A novel interleukin-1 receptor-associated kinase 4 from blunt snout bream (Megalobrama amblycephala) is involved in inflammatory response via MyD88-mediated NF-κB signal pathway
3个月前
已完结
NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases
6个月前
已完结
General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex
7个月前
已完结
皖公网安备34019202002308
